Lite Strategy (NASDAQ:LITS – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings upgraded shares of Lite Strategy from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.
Get Our Latest Stock Analysis on Lite Strategy
Lite Strategy Stock Performance
Lite Strategy (NASDAQ:LITS – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.48 EPS for the quarter.
Hedge Funds Weigh In On Lite Strategy
Several institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new stake in shares of Lite Strategy in the 2nd quarter valued at about $62,000. BlackRock Inc. bought a new stake in shares of Lite Strategy during the 2nd quarter valued at about $254,000. GSA Capital Partners LLP bought a new stake in shares of Lite Strategy during the 2nd quarter valued at about $57,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Lite Strategy by 13.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,744,700 shares of the company’s stock worth $2,024,000 after purchasing an additional 203,278 shares during the last quarter. 52.38% of the stock is currently owned by hedge funds and other institutional investors.
About Lite Strategy
Lite Strategy, Inc. is a digital-asset treasury company focused on acquiring and holding Litecoin as a primary reserve asset. Its business centers on managing this Litecoin-focused strategy rather than providing consumer products or services. The company was formerly known as MEI Pharma, a clinical-stage biopharmaceutical company that worked on treatments for cancer. It later shifted its business focus to a Litecoin treasury strategy. Lite Strategy’s activities therefore primarily involve its digital-asset holdings and related treasury management; the company is not principally engaged in drug development under its current strategy.
Read More
- Five stocks we like better than Lite Strategy
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Lite Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lite Strategy and related companies with MarketBeat.com's FREE daily email newsletter.
